• 한국임상수의학회지
• /
• 제25권5호
• /
• pp.396-399
• /
• 2008

A 2-year-old intact female dachshund dog was presented with recurrent subcutaneous nodules and fistulations on the neck, back and hip. The patient was diagnosed as a sterile nodular panniculitis based on the cytology, histopathology, and cultures for bacteria and fungus. The fistulas were surgically removed and methylprednisolone was administrated 2 mg/kg twice daily per oral. The lesions were all disappeared, but the relapses were happened when the dosage of the drug was tapered off. The repeated treatments with methylprednisolone or azathioprine were performed, consequently, the patient was controlled with relatively low-dosage methylprednisolone (0.25 mg/kg, every third day).

• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2-2
• /
• pp.177.3-177.3
• /
• 2003

Corticosteroids have been used most frequently for inflammatory bowel disease. To reduce side effects by the systemic absorption, colon-specific delivery is highly desirable. We expected that conversion of 21-hydroxyl in glucocorticoids into a sulfate ester sodium will greatly increase the hydrophilicity, which consequently restrict the gastrointestinal absorption. Once delivered to the colon, sulfate ester will be hydrolyzed by the sulfatase originated from microbes and release the parent compound, glucocorticoids. In this study, we prepared methylprednisolone 21-sulfate sodium (MPS) and investigated its suitability as a colon-specific prodrug on methylprednisolone (MP). (omitted)

• Tuberculosis and Respiratory Diseases
• /
• 제46권6호
• /
• pp.775-785
• /
• 1999

목 적 : 폐섬유화증 연구의 동물 실험 모델로 paraquat 중독이 자주 이용되고 있다. 본 연구에서는 paraquat로 유발된 폐섬유화에서 폐섬유화의 정도에 따른 Et-1의 변화를 면역조직화학적으로 관찰하고 스테로이드나 cyclophosphamide의 치료에 따른 Et-1의 변화를 관찰하여 폐섬유화과정에 Et-1의 역할을 밝히고자 하였다. 대상 및 방법 : 수컷 Hartley 기니픽을 4군으로 나누어 실험하였다. I 군은 paraquat를 투여하지 않은 군이었고, II 군용 paraquat를 폐에 주입한 후 cyclophosphamide와 methylprednisolone을 투여한 군이었고 III 군은 paraquat를 폐에 주입한후 methylprednisolone만 투여하였고, IV 군은 paraquat만 투입하였다. I 군을 제외한 나머지 군에서는 PE50 polyethylene tube를 이용하여 paraquat를 우측 폐로 주입하였다. 섬유화의 정도는 H-E와 Masson's trichrome 염색을 통해서 섬유아세포의 침윤정도와 교원질의 침윤정도로 판단하였고, Endothelin-1 면역조직화학염색을 통해서 세포의 활성도를 평가하였다. 각 군의 평균값은 median 값으로 표시하였고, 각 군간의 비교는 Kruskal-Wallis oneway analysis로 시행하였다. 결 과 : 1. Paraquat에 의한 폐 섬유화 Cyclophosphamide나 methylprednisolone의 치료로 paraquat에 의한 섬유아세포의 증식이 억제되었으나 통계학적 의미는 없었다. 교원질의 침윤은 cyclophosphamide와 methylprednisolone을 병합한 경우 paraquat만 투여한 군보다 의미있게 감소하였다(p<0.05). 2. Endothelin-1에 대한 면역조직화학염색 Paraquat의 투여로 발생된 폐섬유화증에 대한 치료의 종류에 따른 Et-1의 발현은 methylprednisolone의 단독 투여로도 폐포의 대식세포를 제외한 기관지 상피세포, 제2형 폐포세포, 혈관 내피세포 및 섬유아세포 등에서 Et-1의 발현이 감소하는 경향을 보였으며, cyclophosphamide와 methylprednisolone을병합한 군에서는 모든 세포에서 의미있게 Et-1의 발현이 감소하였고, 특히 폐포 대식세포와 섬유아세포에서는 methylprednisolone의 단독 투여한 III 군보다 의미있게 감소하였다(Table 2, p<0.05).

• Clinical and Experimental Pediatrics
• /
• 제49권4호
• /
• pp.455-459
• /
• 2006

급성 호흡곤란 증후군은 다양하게 유발되는 신체의 손상에 대한 방어기전으로 염증반응이 유발되어 생성되는 폐포 내의 부종으로 인해 호흡곤란과 저산소증이 초래되는 질환이다. 이 질환에서 표면활성제의 결핍과 폐포 표면 장력의 증가로 인해 폐포 동원에 장애가 오는 것이 결정적인 병인이고 표면활성제의 보충이 저산소증을 개선시킴으로써 중요한 치료 방안이 될 수 있다는 가설이 제시되었고 실제로 소아 환자들에서 저산소증을 개선시키고 증상의 호전을 얻었던 보고들이 여러 차례 있었다. 또한 이 질환의 주요 병인인 폐에서의 염증 반응에 주안점을 두고 스테로이드를 투여해 본 연구들에서 저용량 methylprednisolone으로 증상이 호전되고 생존율이 향상되었다는 결론을 얻은 바 있으나 두 치료 모두 ARDS에서 일반적인 적용은 확립되어 있지 않은 실정이다. 저자들은 급성 호흡곤란 증후군으로 진단받은 61일된 소아가 인공 호흡기 등의 보존적인 치료에 반응하지 않고 지속적으로 증상의 악화를 보이다가 표면활성제 120 mg/kg를 기도 내로 주입한 후 호흡곤란 증상과 저산소증 호전되고 $PaO_2/FiO_2$ 상승, 이후 저용량 methylprednisolone을 투여(2 mg/kg 14일간, 1 mg/kg 7일간, 0.5 mg/kg 7일간, 0.25 mg/kg 2일간, 0.125 mg/kg/d 2일간)한 후 2개월간의 추적 관찰에서 증상의 재발없고 방사선학적 검사상 섬유화 등의 합병증을 보이지 않았던 1례를 보고하는 바이다.

• Journal of Chest Surgery
• /
• 제27권1호
• /
• pp.15-23
• /
• 1994

This study examined the effects of cyclosporin A [CsA] and methylprednisolone[MP] on the viability of the devascularized trachea after heterotopic transplantation. Fourty-two tracheal segments were harvested from 21 donor Wistar rats. Those tracheal segments were heterotopically implanted into the abdomen of recipient rats after wrapping in omentum. Heterotopical implantation was performed in six groups of rats:Group I was Wistar syngeneic controls, and five groups of Sprague Dawley recipients, receiving no immunosuppression[Group II], CsA alone[Group III, V], and CsA in combination with MP[Group IV, VI]. After 14 days, the tracheal segments were histologically evaluated.Epithelial thickness and the degree of epithelial regeneration were significantly different between group I and group II, III, VI, VI [p< 0.05]. There were significant differences in the epithelial thickness between group II, III, IV and group V, VI. In the degree of epithelial regeneration, there were significant differences in group II, group III-IV, and group V-VI. Without immunosuppression there was virtually no epithelium, whereas low-dose immunosuppression yielded intermediated viability, and with high dose CsA and MP we observed improved tracheal viability. Our results suggest that optimal combination of CsA and MP may improve the viability in heterotopic tracheal allografts.

• The Korean Journal of Pain
• /
• 제33권2호
• /
• pp.192-198
• /
• 2020

Background: Previous studies have shown varying results between lumbosacral transforaminal epidural steroid injections (TFESIs) performed with particulate versus non-particulate corticosteroids. The purpose of this study was to investigate the difference in pain relief and functional improvement between particulate and nonparticulate lumbosacral TFESIs in patients who had undergone both injections, sequentially. Methods: This was a self-controlled, retrospective study of 20 patients who underwent both a methylprednisolone and a dexamethasone TFESI to the same vertebral level and side. Primary outcomes included pain relief according to the visual analogue scale (VAS) and functional improvement determined by a yes/no answer to questions regarding mobility and the activities of daily living. Post-injection data was recorded at 2, 3, and 6 months. Results: A decrease in VAS scores of -3.4 ± 3.0 (mean ± standard deviation), -3.1 ± 3.1, and -2.8 ± 3.4 was seen for the methylprednisolone group at 2, 3, and 6 months, respectively. Similar decreases of -3.9 ± 3.5, -3.4 ± 2.8, and -2.3 ± 3.4 were seen in the dexamethasone group. There was no significant difference in pain relief at any point between the two medications. The percentage of subjects who reported improved function at 2, 3, and 6 months was 65%, 51%, and 41%, respectively, for the methylprednisolone group and 75%, 53%, and 42% for the dexamethasone group. Conclusions: These findings support the use of non-particulate corticosteroids for lumbosacral TFESIs in the context of documented safety concerns with particulate corticosteroids.

• 대한의생명과학회지
• /
• 제8권3호
• /
• pp.195-202
• /
• 2002

Osteoarthritis (OA), the most common form of arthritis, involves the destabilization of the normal balance between the degradation and the synthesis of articular cartilage and subchondral bone within a joint. As articular cartilage degrades over time, its smooth surface roughens and bone-against-bone contact ensues, producing the inflammation response symptomatic of this 'wear and tear' disease. Although a variety of genetic, developmental, metabolic, and traumatic factors may initiate the development of osteoarthritis, its symptoms (joint pain, stiffness, and curtailed function) typically evolve slowly, and patients experience periods of relative calm alternation with episodes of inflammation and pain. Rheumatoid arthritis (RA), an autoimmune disease of unknown etiology characterized by chronic synovitis and cartilage destruction, affect 1% of the total population. Cartilage is a specialized connective tissue in which the chondrocytes occupy only 5% of the volume. Cartilage is particularly rich in extracellular matrix, with matrix making up 90% of the dry weight of the tissue chondrocytes have cell processes that extend a short distance into the matrix, but do not touch other cells thus in cartilage, cell-matrix interactions are essential for the maintenance of the extracellular matrix. In this study, subtractive hybridization method was utilized to detect genes differentially expressed in chondrocytes treated with methylprednisolone. We have isolated 57 genes that expressed differentially in the chondreocytes by methylprednisolone. 13 clones of them were analyzed with sequencing and their homologies were searched. 8 cDNAS included KIAA 0368, upregulated during skeletal muscle growth 5 (usmg 5), ribosomal protein S 18 (RPS 18), skeletal muscle ryanodine receptor, radial spoke protein 3 (RSP 3), ribosomal protein QM, ribosomal protein L37a (RPL37A), cytochrome coxidase subunit VIII (COX8).

• 대한의생명과학회지
• /
• 제16권2호
• /
• pp.105-112
• /
• 2010

Methylprednisolone (MPD) is a synthetic glucocorticoid drug used in treatment of many neurological diseases and neurotraumas, including spinal cord injuries. Little is known of the mechanism of MPD in neuronal cells, particularly the genetic expression aspect. DD-PCR was used in identification of genes expressed during MPD treatment of PC12 cells. We have isolated 3 predicted up- or down-regulated genes, which are differentially expressed in neurons by MPD. One of these genes, USP16 (ubiquitin specific protease 16), is the deubiquitinating enzyme that is up-regulated by MPD in neurons. In order to observe the effect of MPD on USP16 gene expression, PC12 cells were treated under several experimental conditions, including endoplasmic reticulum stress drugs. We have isolated the total RNAs in PC12 cells and detected USP16 and ER related genes by RT-PCR. Because its expression pattern is similar to expression of ER chaperons, USP16 gene expression is strongly associated with unfolded protein response. A meaningful negative effect on each tissue treated by methylprednisolone is not shown in vivo. USP16 gene expression is suppressed by LY294002 (phosphatidylinositol 3-kinase inhibitor), which suggests that USP16 gene expression is regulated by the phosphatidylinositol 3-kinase pathway.

• 대한골관절종양학회지
• /
• 제4권1호
• /
• pp.44-52
• /
• 1998

We treated 19 cases of unicameral bone cysts with methylprednisolone acetate (MPA) from January 1988 to December 1995. We evaluated the effect of MPA injections through simple follow-up radiographs according to Oppenheim's, classification and retrospectively reviewed the sites of cyst, age of the patients at diagnosis, the incidence of pathologic fracture, cystic nature, and cystic proximiy to the growth plate, We then analyzed the relationship between these variables with the results of MPA injections. According to Oppenheim's classification, the results with the use of MPA injections were as follows: healed in six cases, improved in seven cases, incomplete obliteration in five cases and recurred in one case, If healed and improved were considered satisfactory results, then 13 cases(68.4%) were satisfactory at the last follow-up. Sites of cyst, age of the patients at diagnosis, incidence of pathologic fracture, cystic nature and cystic proximiy to the growth plate appeared not to influence the results of MPA injections statistically. On these data, we thought that the treatment of unicameral bone cysts with MPA injection was the most effective first choice of treatment before operative options such as curettage and bone graft.

• 한국임상수의학회지
• /
• 제25권6호
• /
• pp.440-446
• /
• 2008

Glucocorticoids (GCs) are the most widely used immunosuppressive agents, but animals treated with GCs may experience deleterious side effects which limit their use in many clinical conditions. In the present study, we examined whether methylprednisolone sodium succinate (MPSS), a glucocorticoid, modulates circulating leukocyte numbers, phagocytic capacity and oxidative burst activity (OBA) of canine peripheral blood phagocytes, and whether tumor necrosis factor-alpha (TNF-$\alpha$) release is affected by MPSS injection. Neutrophilia and monocytosis were induced by the administration of a high dose of MPSS, which is the recommended protocol for canine patients with acute spinal cord injury. The injection of MPSS decreased the phagocytic capacity of canine PMNs but not PBMCs, and recovered 12 hours (hr) after the completion of MPSS dosing. The OBA of both PMNs and PBMCs was suppressed by MPSS, and restored 24 hr after the completion of dosing. The lipopolysaccharide-induced TNF-α release by PBMCs but not PMNs exposed to MPSS was reduced 12 hr after the completion of dosing, and recovered 48 hr after the completion of dosing. These results suggest that the application of MPSS protocol inhibits the innate immune functions of canine peripheral blood phagocytes for short time relatively.